Evidence map›Paper›PMID 41283615›Full record

ArticlePharmacy (Basel, Switzerland)2025

Peer-Delivered Hepatitis C Testing and Health Screening Provided in a Community Pharmacy Setting: Proof of Concept.

Neha Sankla, Ray Cottington, Chris Cowie, Paul Huggett, Leila Reid, Stuart Smith, Sorcha Daly, Danny Morris, James Spear, Amanda Marsden and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacy (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Neha SanklaPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol BS8 2PS, UK.ORCID 0009-0005-2733-4347
Ray CottingtonHepatitis C Trust, 72 Weston Street, London SE1 3HQ, UK.
Chris CowieHepatitis C Trust, 72 Weston Street, London SE1 3HQ, UK.
Paul HuggettHepatitis C Trust, 72 Weston Street, London SE1 3HQ, UK.
Leila ReidHepatitis C Trust, 72 Weston Street, London SE1 3HQ, UK.
Stuart SmithHepatitis C Trust, 72 Weston Street, London SE1 3HQ, UK.ORCID 0000-0003-0695-4692
Sorcha DalyHepatitis C Trust, 72 Weston Street, London SE1 3HQ, UK.
Danny MorrisHepatitis C Trust, 72 Weston Street, London SE1 3HQ, UK.
James SpearODN Leicester & Northampton Hepatitis C Network, University Hospitals Leicester NHS Trust, Leicester LE1 5WW, UK.
Amanda MarsdenGastroenterology Department, Northampton General Hospital, Northampton NN1 5BD, UK.
David RichardsGastroenterology Department, Northampton General Hospital, Northampton NN1 5BD, UK.
Rachel HalfordHepatitis C Trust, 72 Weston Street, London SE1 3HQ, UK.
Scott WalterNational Institute for Health and Care Research, Applied Research Collaboration West (NIHR ARC West), University Hospitals Bristol and Weston NHS Foundation Trust, Bristol BS1 2NT, UK.
Jenny ScottCentre for Academic Primary Care, Bristol Medical School, University of Bristol, Bristol BS8 2PS, UK.ORCID 0000-0002-4920-0914

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In order to reach and maintain hepatitis C virus (HCV) elimination goals, it is imperative to reach marginalized people who do not engage with traditional testing and treatment. Peer-led interventions are effective in engaging such individuals. Studies have demonstrated community pharmacy as a low-threshold setting for HCV testing, but pharmacy teams' competing demands are a barrier to maximizing potential. This pilot project aimed to assess whether a pharmacy-based peer-led model of HCV testing was implementable, deliverable, able to engage marginalized people, and overcome pharmacy staff constraints. We implemented a peer-led HCV testing service in one community pharmacy in the Midlands, England, providing four focused phases of testing, totalling 198 h, over two years. In total, 591 tests for antibodies or RNA were undertaken, identifying 24 active infections. Subsequent phases retested 20%, 16%, and 11% of those tested in combined preceding phases. In response to feedback, phases 3 and 4 included health screening (blood pressure, cholesterol, diabetes, and nurse-performed Fibroscans

Indexed as

community pharmacyhealth screeninghepatitis C testingprimary care

Identifiers

PMID41283615
PMCPMC12641759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.